Generex Biotechnology Corp. GNBT Company Overview Stock

New Post Public Reply Private Reply Replies (0) Message Board

Sep 6, 2013 at 4:59 PM

Generex Biotechnology Corp. GNBT Company Overview

Stock Message Board http://investorshangout.com/search?q=GNBT&...mp;yt1=Go!

Generex Biotechnology Corp. GNBT Current Price and Quotes
Last Price 0.032
Previous Close 0.031 Open 0.03
Daily Range 0.033 - 0.0305 52wk Range 0.085 - 0.02
Volume 635,097 Dividend N/A
Average Vol (3m) 2,881,434 Yield N/A
Generex Biotechnology Corp. GNBT

Company Verified Profile
Company Information

555 Richmond Street West
Suite 604
Toronto, ONT M5V 3B1
Canada

Website: http://www.generex.com
Phone: 416-364-2551
Email: info@generex.com

Generex Biotechnology Corp. GNBT
Generex Biotechnology Corp. GNBT
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Not Available
Latest Report Apr 30, 2013 10-Q
CIK 0001059784
Fiscal Year End 7/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts

Mark Fletcher CEO, President
David Brusegard COO
Stephen Fellows CFO
Todd Falls Corp. Mktg. & IR Manager
Company Directors

John P. Barratt Chairman
Mark Fletcher
Company Notes

Note=4-99 State of Incorporation Idaho changed to Delaware
Formerly=Green Mt P.S. Inc. until 1-98
Service Providers

Auditor/Accountant
MNP LLP
1055 Dunsmuir Street
Suite 2300
Vancouver, BC, V7X 1J1
Canada

Legal Counsel
Not Available
Investor Relations Firm
Not Available

Generex Biotechnology Corp. GNBT
GNBT Security Details

Share Structure

Market Value1 $16,477,284 a/o Sep 05, 2013
Shares Outstanding 531,525,287 a/o Jun 07, 2013
Float Not Available
Authorized Shares Not Available
Par Value 0.001
Shareholders

Shareholders of Record 596 a/o Oct 15, 2012
Short Selling Data

Short Interest 49,307 (-34.21%)
Aug 15, 2013
Significant Failures to Deliver No
Transfer Agent(s)

Broadridge Financial Solutions, Inc.

Generex Biotechnology Corp. GNBT Recent News

Aug 20, 2013 Generex Announces Publication of Follow-up Studies from Phase I Trial of Novel Immunotherapeutic in Prostate Cancer Patients
Aug 13, 2013 Generex Announces Podium Presentation on Antigen Express Cancer Vaccine Strategy
Aug 12, 2013 Generex Provides Call-In Details for Conference Call with Members of the Antigen Express Scientific Advisory Board
Aug 9, 2013 OTC Daily Alert Stock Watch - Generex (OTCQB:GNBT)
Jul 23, 2013 Generex Confirms Conference Call with Members of the Antigen Express Scientific Advisory Board
Jul 12, 2013 Generex Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
Jul 10, 2013 Generex Oral-lyn(TM) Results in More Rapid Reductions of HbA1c in Shreya's Phase III Study of Type 2 Diabetes in India
Jul 8, 2013 Generex Announces Conference Call with Members of Generex Oral-lyn(TM) and Diabetes Program Team
Jul 3, 2013 Generex Announces Amendment of Form S-1
Jul 1, 2013 Generex Announces Conference Call with Members of the Antigen Express Scientific Advisory Board

1
2
next >

Generex Biotechnology Corp. GNBT Financials
Period Ending Jul 31, 2012 Jul 31, 2011 Jul 31, 2010 Jul 31, 2009
Total Revenue 29 292 1,173 1,119
Cost of Revenue 11 156 812 528
Gross Profit 18 136 360 591
Operating Expenses

Research and Development 4,987 10,250 13,361 13,562
Sales, General and Admin. 5,054 14,419 16,429 13,285
Non-Recurring Items - - - -
Other - - - -
Operating Income (10,024) (24,533) (29,430) (26,256)
Income From Continuing Operations

Add'l Income/Expense Items 1,126 3,066 4,360 559
Earnings Before Interest and Tax (8,898) (21,467) (25,070) (25,698)
Interest Expense 593 209 210 20,115
Earnings Before Tax (9,490) (21,676) (25,280) (45,812)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (9,490) (21,676) (25,280) (45,812)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (9,490) (21,676) (25,280) (45,812)
Preferred Stock and Other Adjustments (377) (766) - -
Net Income Applicable to Common Shareholders (9,867) (22,442) (25,280) (45,812)

GNBT Generex Biotechnology Corp. Research DD Guide

GNBT Generex Biotechnology Corp. Stock Message Board http://investorshangout.com/search?q=GNBT&...mp;yt0=Go!
GNBT Generex Biotechnology Corp. Stock Quote http://www.otcmarkets.com/stock/GNBT/quote
GNBT Generex Biotechnology Corp. Stock Chart http://www.otcmarkets.com/stock/GNBT/chart
GNBT Generex Biotechnology Corp. Company Info http://www.otcmarkets.com/stock/GNBT/company-info
GNBT Generex Biotechnology Corp. Recent News http://www.otcmarkets.com/stock/GNBT/news
GNBT Generex Biotechnology Corp. Financials http://www.otcmarkets.com/stock/GNBT/financials
GNBT Generex Biotechnology Corp. Filings and Disclosure http://www.otcmarkets.com/stock/GNBT/filings
GNBT Generex Biotechnology Corp. Short Sales http://www.otcmarkets.com/stock/GNBT/short-sales
GNBT Generex Biotechnology Corp. Insider Disclosure http://www.otcmarkets.com/stock/GNBT/insider-transactions
GNBT Generex Biotechnology Corp. Research Reports http://www.otcmarkets.com/stock/GNBT/research
GNBT Generex Biotechnology Corp. Summary http://finance.yahoo.com/q?s=GNBT
GNBT Generex Biotechnology Corp. Historical Prices http://finance.yahoo.com/q/hp?s=GNBT+Historical+Prices
GNBT Generex Biotechnology Corp. Interactive Chart http://finance.yahoo.com/echarts?s=GNBT
GNBT Generex Biotechnology Corp. Basic Chart http://finance.yahoo.com/q/bc?s=GNBT+Basic+Chart
GNBT Generex Biotechnology Corp. Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=GNBT+Basic+Tech.+Analysis
GNBT Generex Biotechnology Corp. Headlines http://finance.yahoo.com/q/h?s=GNBT+Headlines
GNBT Generex Biotechnology Corp. Press Releases http://finance.yahoo.com/q/p?s=GNBT+Press+Releases
GNBT Generex Biotechnology Corp. Company Profile http://finance.yahoo.com/q/pr?s=GNBT+Profile
GNBT Generex Biotechnology Corp. Key Statistics http://finance.yahoo.com/q/ks?s=GNBT+Key+Statistics
GNBT Generex Biotechnology Corp. Industry http://finance.yahoo.com/q/in?s=GNBT+Industry
GNBT Generex Biotechnology Corp. Major Holders http://finance.yahoo.com/q/mh?s=GNBT+Major+Holders
GNBT Generex Biotechnology Corp. Insider Transactions http://finance.yahoo.com/q/it?s=GNBT+Insider+Transactions
GNBT Generex Biotechnology Corp. Insider Roster http://finance.yahoo.com/q/ir?s=GNBT+Insider+Roster
GNBT Generex Biotechnology Corp. Income Statement http://finance.yahoo.com/q/is?s=GNBT
GNBT Generex Biotechnology Corp. Balance Sheet http://finance.yahoo.com/q/bs?s=GNBT
GNBT Generex Biotechnology Corp. Cash Flow http://finance.yahoo.com/q/cf?s=GNBT+Cash+Flow&annual
GNBT Generex Biotechnology Corp. Nasdaq http://www.nasdaq.com/symbol/GNBT
GNBT Generex Biotechnology Corp. Market Watch http://www.marketwatch.com/investing/stock/GNBT
GNBT Generex Biotechnology Corp. Bloomberg http://www.bloomberg.com/quote/GNBT:US
GNBT Generex Biotechnology Corp. Morningstar http://quotes.morningstar.com/stock/s?t=GNBT
GNBT Generex Biotechnology Corp. Bussinessweek http://investing.businessweek.com/research/st...icker=GNBT
GNBT Generex Biotechnology Corp. Barchart http://www.barchart.com/quotes/stocks/GNBT
GNBT Generex Biotechnology Corp. OTC Short Report http://otcshortreport.com/index.php?index=GNBT
GNBT Generex Biotechnology Corp. Investopedia http://www.investopedia.com/markets/stocks/GNBT/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...

Special Needs Group Partners with MAST to Enhance Accessibility

Accessible Travel Takes the Spotlight Ah, the travel biz—just when you think you’ve got it all figured out, along comes a partnership like this to shake things up. Special Needs Group, the big cheese in mobility and medical equipment rentals, is teaming up with MAST Travel Network. Together, they're rolling out initiatives to make the world a bit more accessible, even...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Fluence Energy Faces Major Lawsuit Amid $3B Loss

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

TechCrunch Disrupt 2026: NYSE and Snowflake Highlights

Ever noticed how the air vibrates just a bit more when major players like NYSE and Snowflake start shaking hands at big-league events like TechCrunch Disrupt? You'd better believe we're seeing a fresh brew of opportunities and challenges in the market as these titans lock horns and share insights. It's no small feat when the financial nerve center partners into the tech...

AtWork Welcomes Franchise Vet Sarah Goehring

A Strategic Move for AtWork There's a new heavyweight at AtWork, a name that's been catching attention in the franchise biz lately—Sarah Goehring. This isn't just another appointment; it's a signal flare for AtWork's ambitions. With Goehring, they're doubling down on scaling their operation and drawing in more franchise players who are ready to hit the ground running....

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

New Data on SKYRIZI Offers Hope for Crohn's Patients

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...